Jerry Andrew Taylor

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 10.4

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

8 out of 2,405

Merck Sharp + Dohme Corp.

patents

2 out of 86

Lexicon Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11014920 - Factor XIIa inhibitors (2021-05-25),

2. 11008313 - Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders (2021-05-18),

3. 10875851 - Factor XIIa inhibitors (2020-12-29),

4. 9567333 - Triazolopyridyl compounds as aldosterone synthase inhibitors (2017-02-14),

5. 9522141 - Indazole compounds as aldosterone synthase inhibitors (2016-12-20),

6. 9518055 - Imidazopyridyl compounds as aldosterone synthase inhibitors (2016-12-13),

7. 9193724 - Triazolopyridyl compounds as aldosterone synthase inhibitors (2015-11-24),

8. 9073929 - Aldosterone synthase inhibitors (2015-07-07),

9. 8093246 - O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer (2012-01-10),

10. 8093245 - 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use (2012-01-10),

Title: Jerry Andrew Taylor: Innovator in Pharmaceutical Chemistry

Introduction

Jerry Andrew Taylor is a notable inventor based in Trenton, NJ (US), recognized for his significant contributions to pharmaceutical chemistry. With a total of 10 patents to his name, Taylor has made remarkable advancements in the field, particularly in the development of compounds that target critical health issues.

Latest Patents

Among his latest patents, Taylor has developed selective Factor XIIa inhibitors. This invention provides a compound of Formula I and pharmaceutical compositions that can be used for treating or preventing thromboses, embolisms, hypercoagulability, or fibrotic changes. These compounds are essential in addressing various cardiovascular conditions. Another significant patent involves substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders. This invention relates to PCSK9 allosteric binding compounds and their use in treating atherosclerosis, hypercholesterolemia, and other related cardiovascular diseases. The invention also includes methods for inducing PCSK9 protein degradation and provides a means for the in vitro labeling, detection, and quantification of PCSK9 in biological samples.

Career Highlights

Throughout his career, Jerry Andrew Taylor has worked with prominent companies such as Merck Sharp & Dohme Corporation and Lexicon Pharmaceuticals, Inc. His work in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Taylor has collaborated with notable colleagues, including Yusheng Xiong and Scott B Hoyt. These partnerships have further enhanced his research capabilities and innovation in the field.

Conclusion

Jerry Andrew Taylor's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a significant innovator in the industry. His work continues to impact the development of treatments for critical health conditions.

This text is generated by artificial intelligence and may not be accurate.